Results 51 to 60 of about 38,894 (153)

Table_4_Evidence for broad cross-reactivity of the SARS-CoV-2 NSP12-directed CD4+ T-cell response with pre-primed responses directed against common cold coronaviruses.xlsx

, 2023
IntroductionThe nonstructural protein 12 (NSP12) of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has a high sequence identity with common cold coronaviruses (CCC).MethodsHere, we comprehensively assessed the breadth and ...
Marylyn Martina Addo (9161949), Alba Grifoni (3137199), Tim Westphal (15414689), Marc Lütgehetmann (6807842), Sophia Schulte (9302936), Leon Cords (12446253), Maria Mader (12629043), Lennart Hermanussen (11096391), Alessandro Sette (19132), Maximilian Knapp (15414692), Vanessa Ditt (199087), Samuel Huber (56057), Hendrik Karsten (11441924), John Sidney (19127), Julian Schulze zur Wiesch (8343450), Sven Peine (3545648), Sven Pischke (511653), William W. Kwok (7380419)   +17 more
core   +1 more source

Image_2_Evidence for broad cross-reactivity of the SARS-CoV-2 NSP12-directed CD4+ T-cell response with pre-primed responses directed against common cold coronaviruses.tif

, 2023
IntroductionThe nonstructural protein 12 (NSP12) of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has a high sequence identity with common cold coronaviruses (CCC).MethodsHere, we comprehensively assessed the breadth and ...
Marylyn Martina Addo (9161949), Alba Grifoni (3137199), Tim Westphal (15414689), Marc Lütgehetmann (6807842), Sophia Schulte (9302936), Leon Cords (12446253), Maria Mader (12629043), Lennart Hermanussen (11096391), Alessandro Sette (19132), Maximilian Knapp (15414692), Vanessa Ditt (199087), Samuel Huber (56057), Hendrik Karsten (11441924), John Sidney (19127), Julian Schulze zur Wiesch (8343450), Sven Peine (3545648), Sven Pischke (511653), William W. Kwok (7380419)   +17 more
core   +1 more source

Antivirals Targeting Coronavirus RNA‐Dependent RNA Polymerase and Main Protease: From Mechanisms of Action to Outcomes in COVID‐19 Clinical Trials

Microbial Biotechnology, Volume 19, Issue 4, April 2026.
The target sites of COVID‐19 antivirals discussed in the present opinion paper, namely the RNA dependent RNA polymerase Nsp12 and of the main viral protease Nsp5, are indicated by a red star in the overview of the replication cycle of coronavirus SARS‐CoV‐2.
Harald Brüssow
wiley   +1 more source

Suramin, penciclovir, and anidulafungin exhibit potential in the treatment of COVID-19 via binding to nsp12 of SARS-CoV-2

, 2021
COVID-19, for which no confirmed therapeutic agents are available, has claimed over 48,14,000 lives globally. A feasible and quicker method to resolve this problem may be ‘drug repositioning’. We investigated selected FDA and WHO-EML approved drugs based
Sanjay Kumar Dey (10967439), Hirendra Kumar Das (11715449), Shruti Bhatt (11715440), Varnita Anand (11715446), Chetna Dhembla (11715437), A. Sai Rajesh (11715443), Manisha Saini (345240), Suman Kundu (199925)   +7 more
core   +2 more sources

Table_2_Evidence for broad cross-reactivity of the SARS-CoV-2 NSP12-directed CD4+ T-cell response with pre-primed responses directed against common cold coronaviruses.xlsx

, 2023
IntroductionThe nonstructural protein 12 (NSP12) of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has a high sequence identity with common cold coronaviruses (CCC).MethodsHere, we comprehensively assessed the breadth and ...
Marylyn Martina Addo (9161949), Alba Grifoni (3137199), Tim Westphal (15414689), Marc Lütgehetmann (6807842), Sophia Schulte (9302936), Leon Cords (12446253), Maria Mader (12629043), Lennart Hermanussen (11096391), Alessandro Sette (19132), Maximilian Knapp (15414692), Vanessa Ditt (199087), Samuel Huber (56057), Hendrik Karsten (11441924), John Sidney (19127), Julian Schulze zur Wiesch (8343450), Sven Peine (3545648), Sven Pischke (511653), William W. Kwok (7380419)   +17 more
core   +1 more source

Allosteric Inhibitors of SARS‐CoV‐2 RNA‐Dependent RNA Polymerase Based on N,N′‐Diphenylurea

ChemMedChem, Volume 21, Issue 1, January 2026.
Inhibitors of SARS‐CoV‐2 RdRp activity based on N,N′‐diphenylurea scaffold have been identified. Several compounds exhibit residual activity (RA) below 50% in an enzymatic assay (at 10 µM concentration) and improved aqueous solubility compared to the previously reported series of inhibitors.
Artem Chayka, Matěj Danda, Alžběta Dostálková, Vojtěch Spiwok, Lamija Zijadic, Anna Klimešová, Marina Kapisheva, Michala Zgarbová, Jan Weber, Tomáš Ruml, Michaela Rumlová, Zlatko Janeba   +11 more
wiley   +1 more source

Image_1_Evidence for broad cross-reactivity of the SARS-CoV-2 NSP12-directed CD4+ T-cell response with pre-primed responses directed against common cold coronaviruses.tif

, 2023
IntroductionThe nonstructural protein 12 (NSP12) of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has a high sequence identity with common cold coronaviruses (CCC).MethodsHere, we comprehensively assessed the breadth and ...
Marylyn Martina Addo (9161949), Alba Grifoni (3137199), Tim Westphal (15414689), Marc Lütgehetmann (6807842), Sophia Schulte (9302936), Leon Cords (12446253), Maria Mader (12629043), Lennart Hermanussen (11096391), Alessandro Sette (19132), Maximilian Knapp (15414692), Vanessa Ditt (199087), Samuel Huber (56057), Hendrik Karsten (11441924), John Sidney (19127), Julian Schulze zur Wiesch (8343450), Sven Peine (3545648), Sven Pischke (511653), William W. Kwok (7380419)   +17 more
core   +1 more source

Naïve Edible PVLNs: Emerging Versatile Biomaterial in Clinical Strategy

IET Nanobiotechnology, Volume 2026, Issue 1, 2026.
Naïve edible plant vesicle‐like nanoparticles (PVLNs) could be acted as innovative therapeutic strategies due to their versatile role, such as antitumor, antiaging, anti‐inflammation, and drug delivery. The advantages of edible PVLNs have displayed notable benefits including low toxicity, minimal side effects, nonimmunogenicity, and cost‐effective ...
Le Zhou, Junqiu Ma, Jiawei Tian, Yao Xue, Chenyang Hu, Xueyan Zang, Wenrong Xu, Jiajia Jiang, Qilong Zhao   +8 more
wiley   +1 more source

Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites

Antiviral Research, 2020
The rapid global emergence of SARS-CoV-2 has been the cause of significant health concern, highlighting the immediate need for antivirals. Viral RNA-dependent RNA polymerases (RdRp) play essential roles in viral RNA synthesis, and thus remains the target of choice for the prophylactic or curative treatment of several viral diseases, due to high ...
Shannon, Ashleigh, Le, Nhung Thi-Tuyet, Selisko, Barbara, Eydoux, Cecilia, Alvarez, Karine, Guillemot, Jean-Claude, Decroly, Etienne, Peersen, Olve, Ferron, Francois, Canard, Bruno   +9 more
openaire   +4 more sources

Remdesivir in COVID‐19: A Focus on Pediatric Cardiac Patients

Canadian Journal of Infectious Diseases and Medical Microbiology, Volume 2026, Issue 1, 2026.
The coronavirus disease 2019 (COVID‐19) pandemic has presented a significant global health challenge that necessitated the immediate search for various therapeutic modalities. Remdesivir, an antiviral drug inhibiting RNA‐dependent RNA polymerase (RdRp), was among the most heavily used drugs against COVID‐19.
Dima Bsat, Dalia Safi, Mariam Arabi, Mamunur Rahman Malik   +3 more
wiley   +1 more source